Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit You

Showing results (91-100 of 142) with videos related to

Pageof 15
Sort By:
Cancers|July 9, 2022
Predominance of <i>BRCA2</i> Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with <i>BRCA1</i> or <i>BRCA2</i> MutationPascal Pujol, Kevin Yauy, Amandine Coffy, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 24, 2021
Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)Jean-Baptiste Delhorme, Laurent Villeneuve, Olivier Bouché, et al.
Therapeutic Advances in Medical Oncology|December 30, 2025
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancersClaire Chator, Nozomu Yanaihara, Sylvie Chabaud, et al.
British Journal of Cancer|March 15, 2017
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancersEric Angevin, Nicolas Isambert, Véronique Trillet-Lenoir, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 2021
Cutting Edge: mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK Cell Maturation and NumberLaurie Besson, Benoite Mery, Magali Morelle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.
Cancers|March 29, 2023
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis DataEleni Karamouza, Rosalind M Glasspool, Caroline Kelly, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 10, 2025
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2)Ramez N Eskander, Bradley Corr, David Cibula, et al.
Gynecologic Oncology|November 19, 2022
Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trialBenoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
Biomarker Research|March 24, 2021
Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibodyYutaro Kaneko, Ryo Hatano, Naoto Hirota, et al.
Pageof 15

Showing results (91-100 of 142) with videos related to

Sort By:
Pageof 15
Cancers|July 9, 2022
Predominance of <i>BRCA2</i> Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with <i>BRCA1</i> or <i>BRCA2</i> MutationPascal Pujol, Kevin Yauy, Amandine Coffy, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 24, 2021
Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)Jean-Baptiste Delhorme, Laurent Villeneuve, Olivier Bouché, et al.
Therapeutic Advances in Medical Oncology|December 30, 2025
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancersClaire Chator, Nozomu Yanaihara, Sylvie Chabaud, et al.
British Journal of Cancer|March 15, 2017
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancersEric Angevin, Nicolas Isambert, Véronique Trillet-Lenoir, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 2021
Cutting Edge: mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK Cell Maturation and NumberLaurie Besson, Benoite Mery, Magali Morelle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.
Cancers|March 29, 2023
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis DataEleni Karamouza, Rosalind M Glasspool, Caroline Kelly, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 10, 2025
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2)Ramez N Eskander, Bradley Corr, David Cibula, et al.
Gynecologic Oncology|November 19, 2022
Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trialBenoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
Biomarker Research|March 24, 2021
Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibodyYutaro Kaneko, Ryo Hatano, Naoto Hirota, et al.
Pageof 15